Medical technology company Becton, Dickinson and Co. (BDX) on Wednesday posted higher profit for the fourth quarter, bolstered by strong performance at its BD Medical and BD Diagnostics segments. Further, the company issued financial forecast for fiscal 2010.
Q4 results
The Franklin Lakes, New Jersey-based company's fourth-quarter net income was $317.2 million, up 12.4% from $282.2 million a year ago. On a per share basis, earnings grew 15.2% to $1.29 from $1.12 in the same quarter of last year.
Income from continuing operations totaled $305.8 million, an increase of 9.6%, compared to $278.9 million in the prior-year quarter. Per share earnings from continuing operations rose 12.6% to $1.25 from $1.11 in the year-earlier period. On a currency-neutral basis, earnings per share from continuing operations for the latest quarter increased 17%.
On average, 8 analysts polled by Thomson Reuters expected the company to post earnings of $1.85 per share. Analysts' estimates typically exclude special items.
Quarterly revenues advanced 4.7% to $1.89 billion from $1.81 billion reported in the corresponding quarter of the previous year. Excluding the unfavorable impact from foreign currency translation, revenues increased 8%. Seven Wall Street analysts had a consensus revenue estimate of $1.85 billion for the quarter.
Edward Ludwig, Chairman and Chief Executive Officer of BD, said, "The achievement of solid fourth quarter performance, in particular BD Medical and BD Diagnostics, marks the conclusion of another successful year for BD. This strong finish to the year provides a platform for growth in fiscal 2010 and gives us confidence we will achieve our stated long-term goals."
Segment & Geographical Review
The company's BD Medical segment fetched fourth-quarter revenue of $1.01 billion, up 8.2% from $929.6 million a year ago, driven by strong sales of Pharmaceutical Systems products, and solid sales of Medical Surgical Systems products. Excluding the unfavorable impact from foreign currency translation, revenue rose 13%.
Worldwide revenues at the BD Diagnostics segment advanced 4.9% to $580.0 million from $553.1 million in the previous year, led by the sales of safety-engineered devices, cancer diagnostics products and infectious disease testing systems, including flu-related products. Excluding the unfavorable impact from foreign currency translation, revenue grew 8%.
Meanwhile, BD Biosciences segment generated quarterly revenues of $312.2 million, a decline of 5.2%, compared the prior-year's revenue of $329.5 million, as funding constraints continued to impact demand in the U.S. for capital equipment in the research and clinical segments. Excluding the unfavorable impact from foreign currency translation, revenues were up 4%.
Fourth quarter revenues in the U.S. advanced 6.0% to $839.6 million from $792.4 million in the same quarter of last year. Overseas revenues totaled $1.06 billion for the recent quarter, up 3.8% from $1.02 billion reported in the year-earlier quarter.
FY09 Results
For the fiscal year 2009, the company reported net income of $1.23 billion or $4.99 per share, compared to $1.13 billion or $4.46 per share in the previous year.
Income from continuing operations was $1.21 billion or $4.92 per share, higher than the prior-year's income of $1.12 billion or $4.42 per share. Analysts expected earnings of $4.96 per share for the full year.
Annual revenues for fiscal 2009 totaled $7.16 billion, up 1.2% from $7.07 billion reported in the year ended September 30, 2008. Excluding the unfavorable impact from foreign currency translation, revenues were up 5%. Eight Wall Street analysts had a consensus revenue estimate of $7.13 billion for fiscal 2009.
Road Ahead
Looking forward to fiscal 2010, the company projects earnings from continuing operations to increase about 1% - 3%, over adjusted earnings per share from continuing operations, excluding specified items, of $4.95 for fiscal 2009, or 7% - 9% excluding the estimated unfavorable impact from foreign currency translation. BD also expects 2010 revenue to grow about 6%, or 5% - 6% excluding the estimated favorable impact from foreign currency translation. Analysts are looking for earnings of $5.09 per share on revenues of $7.56 billion for the fiscal year 2010.
Peer Performance
Among other players in the sector, CR Bard Inc. (BCR) reported higher third-quarter net income of $129.5 million or $1.31 per share, compared to $111.2 million or $1.08 per share in the prior-year quarter. Net sales increased 3% to $637.00 million from $616.80 million in the previous year. Excluding the impact of foreign exchange, net sales grew 6% over a year ago.
Another peer, Abbott Laboratories (ABT) posted third-quarter net income of $1.48 billion or $0.95 per share, up from $1.09 billion or $0.69 per share in the prior-year quarter, aided by strong sales of its arthritis drug Humira and nutritional products. Net sales increased 3.5% to $7.76 billion from $7.50 billion in the same quarter of last year.
Stock Quotes
Becton, Dickson shares, which have been trading between $58.14 and $77.11 in the past 52 weeks, closed Tuesday's trading session at $69.91, up 96 cents or 1.39%, on a volume of 3.07 million shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.